Bibliography

Export 12 results:
Filters: Keyword is psychosis  [Clear All Filters]
M
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.